Source: Pharmaceutical Business Review

Ironwood Pharmaceuticals: Ironwood Pharmaceuticals and AstraZeneca amend LINZESS (linaclotide) collaboration in China

LINZESS was approved by the National Medical Products Administration for adults with IBS-C in China in January 2019. LINZESS is expected to be launched in China in theThe post Ironwood Pharmaceuticals and AstraZeneca amend LINZESS (linaclotide) collaboration in China appeared first on Pharmaceutical Business review.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Ironwood's latest SEC filings

Annual Revenue

Based on data from Ironwood's latest SEC filings

Employees

Mark Mallon's photo - CEO of Ironwood

CEO

Mark Mallon

CEO Approval Rating

93/100

Ironwood is a drug manufacturer that develops and markets medicines for the treatment of irritable bowel syndrome and ch... Read more